---
format:
  revealjs:
    spotlight: true
    touch: true
    controls: true
    pointer: true
    center-title-slide: false
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: false
    multiplex: false
    chalkboard: true
    theme: [default, custom.scss]
    filters:
     - highlight-text
bibliography: references.bib
lightbox: true
csl: diagnostic-microbiology-and-infectious-disease.csl
---

## Lecture 3: β-lactams and β-lactamases {background-image="images/flemming1.png" background-opacity="0.2"}

<br> <br> <br> <br> <br>

**Russell E. Lewis** <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua

![](unipd.png){.absolute top="550" left="950" width="100" height="100"}

<br> {{< fa solid envelope size=1x >}} russelledward.lewis\@unipd.it <br> {{< fa brands github size=1x >}} [https://github.com/Russlewisbo](https://github.com/Russlewisbo/ESCMID_2022_talk)

## Outline

<br>

-   Antibiotic classes
-   Mechanism of action
-   Pharmacokinetics/Pharmacodynamics
-   Resistance
-   Role in therapy

## Discovery of penicillin

<br> <br>

::::: columns
::: {.column width="50%"}
![](images/pcn2.png)
:::

::: {.column width="50%"}
![Sir Alexander Fleming in his laboratory, Pathé Films](https://i.makeagif.com/media/7-05-2015/V0HT6G.gif)
:::
:::::

::: aside
[@fleming_1929]
:::

## Natural penicillins

![](images/natural%20penicillins.png){fig-align="center" width="800"}

## Isoxazolyl penicillins {.smaller}

![](images/isoxyl%20penicillins.png){fig-align="center" width="700"}

## Aminopenicillins {.smaller}

![](images/amino.png){fig-align="center" width="800"}

## Extended-spectrum penicillins {.smaller}

![](images/extended%20spectrum%20penicillins.png){fig-align="center" width="500"}

## Mechanism of action

<br>

::::: columns
::: {.column width="50%"}
![Inhibition of transpeptidase (PBP)](https://i.makeagif.com/media/4-07-2017/l7_PRO.gif)
:::

::: {.column width="50%"}
![Lysis of growing bacterial cells](https://i.makeagif.com/media/10-05-2017/e3c7kf.gif)
:::
:::::

<br>

## Spectrum of activity {.smaller}

<br> <br>

![](images/pcnspextrum.png){fig-align="center"}

-   **Good:** *Treponema pallidum*, most streptococci, including *Streptococcus pneumoniae*

-   **Moderate:** Enterococci

-   **Poor:** Almost everything else (penicillinases, β-lactamases)

::: aside
Source: Sanford Guide Web

++ Preferred + activity; ± limited utility; 0 not recommended
:::

## Pharmacodynamics of **β-lactam** antibiotics {.smaller background-image="images/killrate.png" background-opacity="0.1"}

<br> <br>

-   **β-lactam antibiotics exhibit relatively concentration-independent killing**
    -   The rate of killing reaches its maximum very quickly as the drug concentration increases from the MIC to 4–6 times the MIC and falls precipitously when the drug concentration decline below the MIC

    -   Related to mechanism of action: acylation of their targets, the β-lactam-binding proteins

    -   There is a maximum proportion of the targets (β-lactambinding proteins) that can be acylated, with a large proportion of the β-lactam-binding proteins already acylated by the time bacterial stasis is achieved

    -   As the percentage of target binding proteins that are acylated increases above the level of acylation that is associated with bacteriostasis, a bactericidal effect is seen

    -   Once maximal acylation is achieved, the killing rates cannot increase any further. This explains why the killing rates for β-lactam drugs are maximal at a low multiple of the MIC
-   [**% Time \> MIC is the pharmacodynamically linked variable**]{bg-color="#ffe536"}
-   **Clinical implications:** Activity of β-lactams with short half-lives is optimized by prolonging drug exposure above the MIC (extended or continuous infusion)

::: aside
[@drusano2004]
:::

## Pharmacokinetics: Natural penicillins {.smaller}

<br> <br>

+-------------------+---------------------------------------------------------------------------------------------------------+
| **Absorption**    | Penicillin VK (oral); bioavailibility 60-73% <br> Penicillin G (IV) <br>Benzathine penicillin (IM) <br> |
+-------------------+---------------------------------------------------------------------------------------------------------+
| **Distribution**  | -   0.35 L/kg                                                                                           |
|                   |                                                                                                         |
|                   | -   65% protein bound                                                                                   |
|                   |                                                                                                         |
|                   | -   500% bile:serum                                                                                     |
|                   |                                                                                                         |
|                   | -   5-10% CSF:blood (therapeutic for some pathogens)                                                    |
+-------------------+---------------------------------------------------------------------------------------------------------+
| **Metabolism**    | -   No metabolism                                                                                       |
|                   |                                                                                                         |
|                   | -   t½ 0.5 hr                                                                                           |
|                   |                                                                                                         |
|                   | -   Substrate of OAT transporters                                                                       |
+-------------------+---------------------------------------------------------------------------------------------------------+
| **Elimination**   | Renal 100%, impaired by probenicid                                                                      |
+-------------------+---------------------------------------------------------------------------------------------------------+
| **Typical doses** | (Pen VK) 250-500 mg TID-QID before meals and at bedtime                                                 |
|                   |                                                                                                         |
|                   | (Low dose) 600,000-1.2 MU IM/day                                                                        |
|                   |                                                                                                         |
|                   | (High dose) Penicillin G: \> 20 MU IV daily                                                             |
+-------------------+---------------------------------------------------------------------------------------------------------+

::: aside
Source: Sanford Guide
:::

## CNS Toxicities {.smaller}

![](images/seizues.png){fig-align="center"}

The β-lactam ring structure is an important determinant of the epileptogenic properties. Evidence suggests that substitutions occurring at the 7-aminocephalosporanic or 6- aminopenicillanic acid (6-APA) positions may lead to alterations in epileptogenic activity. The thiazolidine ring and side chain length also plays a role in determining the pro-convulsive effects of β-lactams

::: aside
[@wanleenuwat2020]
:::

## Other adverse effects

<br>

-   Most serious reaction is immediate IgE-mediated anaphylaxis; incidence only 0.05% but 5-10% fatal. Other IgE-mediated reactions: urticaria, angioedema, laryngeal edema, bronchospasm

    -   Morbilliform rash after 72 hours is not IgE-mediated and not serious

-   Serious late allergic reactions: Coombs-positive hemolytic anemia, neutropenia, thrombocytopenia, serum sickness, interstitial nephritis, hepatitis, eosinophilia, drug fever

## Clinical role {.smaller}

<br>

-   Poor empiric choice for most infections because of resistance

-   Drug of choice for syphilis particularly neurosyphilis (although use of ceftriaxone is increasing)

<br>

## Pharmacokinetics:  <br>Anti-staphylococcal penicillins {.smaller}

<br> <br>

+-------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Absorption**    | Dicloxacillin (oral- bioavailibility 60-73%) <br> Methicillin (IV-not used); <br> Flucloxacillin (oral and IV, bioavailibility 50%) <br> Nafcillin (IV)<br>Oxacillin (IV) <br> |
+-------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Distribution**  | -   0.1-0.5 L/kg                                                                                                                                                               |
|                   |                                                                                                                                                                                |
|                   | -   \>95% protein bound                                                                                                                                                        |
+-------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Metabolism**    | Not metabolised but some drugs can induce CYP P450 (dicloxacillin, flucloxacillin)                                                                                             |
+-------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Elimination**   | Biliary with some renal (no dosing adjustment for renal impairment)                                                                                                            |
+-------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Typical doses** | 125-500 every 6h (oral); 1-2 gram IV every 4-6h                                                                                                                                |
+-------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

## **Adverse Effects**

<br>

-   Local phlebitis, fever, rash (4%), anaphylaxis (rare)- *problematic with frequent IV dosing*

-   \+ Coombs (rare), neutropenia (prolonged treatment), eosinophilia (22%), thrombocytopenia , *C. difficile* colitis (rare), increased LFTs, headache (rare), confusion (rare), acute interstitial nephritis (less than methicillin)

-   Hepatic dysfunction-more problematic with doses ≥12 gm/day (oxacillin \> nafcillin)

    -   LFTs usually increase 2–24 days after start of treatment, reversible.

## Clinical role

<br>

-   Infections caused by MSSA, such as endocarditis, bloodstream infections, and skin and soft-tissue infections

-   β-lactams kill staphylococci more quickly than vancomycin, so patients with MSSA infections who lack serious beta-lactam allergies should be switched to beta-lactams, such as antistaphylococcal penicillins or first-generation cephalosporins <!--# Double check treatment guidelines -->

<br>

## References
